REVEAL 1.0 (Historical) Subcomponents – Reference Calculators

Clinical calculation support · Verify results before clinical use

Patient parameters

Enter available clinical, laboratory, echocardiographic, and haemodynamic data to view reference bands.

Scope: this is a reference companion for selected PAH prognostic variables, not the original REVEAL 1.0 point-based score and not a stand-alone mortality prediction. Contemporary ESC/ERS bands are identified separately below.

Demographics and PAH classification

Used for eGFR estimation only.

Vitals and functional capacity

Presence, particularly moderate/large effusion, is an adverse prognostic feature.

Biomarkers and renal function

Enter BNP or NT-proBNP, not both.
Biomarker cut-offs are not interchangeable.
Optional; used to estimate eGFR with CKD-EPI 2021.

Right-heart haemodynamics

Displayed descriptively; no ESC/ERS risk band is assigned.

How to interpret these variables

REVEAL is a validated prognostic framework developed for pulmonary arterial hypertension. The historical REVEAL 1.0 model uses a defined point-based algorithm; listing selected variables and assigning contemporary reference bands is not equivalent to calculating that score.

The 2022 ESC/ERS guidelines recommend multiparametric risk assessment. At diagnosis, the three-strata approach integrates clinical observations, WHO functional class, exercise capacity, biomarkers, imaging, and haemodynamics. At follow-up, a four-strata approach based primarily on WHO functional class, 6-minute walk distance, and BNP/NT-proBNP is recommended, with additional data considered as needed.

ESC/ERS three-strata reference bands

VariableLowIntermediateHigh
6MWD>440 m165–440 m<165 m
BNP<50 pg/mL50–800 pg/mL>800 pg/mL
NT-proBNP<300 ng/L300–1100 ng/L>1100 ng/L
Mean RAP<8 mmHg8–14 mmHg>14 mmHg
Cardiac index≥2.5≥2.0 to <2.5 (guideline table: 2.0–2.4)<2.0 L/min/m²
SvO₂>65%60–65%<60%

References

Benza RL, et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the REVEAL Registry.Circulation. 2010;122:164–172. Original REVEAL prognostic model.
Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.European Heart Journal. 2022;43:3618–3731. doi:10.1093/eurheartj/ehac237
Inker LA, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race.New England Journal of Medicine. 2021;385:1737–1749. doi:10.1056/NEJMoa2102953
Clinical disclaimer: This page is educational and does not calculate REVEAL 1.0, REVEAL 2.0, REVEAL Lite 2, or individual mortality probability. Do not base treatment or disposition on isolated bands. Consider the full clinical assessment, right-heart imaging, haemodynamics, comorbidities, PAH aetiology, and specialist judgement. BNP and NT-proBNP thresholds are assay-specific reference categories and the biomarkers are not interchangeable.